Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Remimazolam + alfentanil is a pharmacological combination used for procedural sedation and analgesia, particularly in short surgical interventions such as ophthalmic procedures. Remimazolam is an ultra-short-acting benzodiazepine that functions as a positive allosteric modulator of the GABA-A receptor, providing rapid sedation and quick recovery due to its metabolism by non-specific tissue esterases. Alfentanil is a potent, short-acting synthetic opioid that acts as an agonist at the mu-opioid receptor, providing rapid-onset analgesia. The combination is designed to leverage the synergistic effects of a sedative and an analgesic to maintain hemodynamic stability and patient comfort during surgery. Clinical research conducted by institutions like Hangzhou Plastic Surgery Hospital has explored this combination as an alternative to propofol-based regimens for eye surgery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on remimazolam + alfentanil.